Related references
Note: Only part of the references are listed.Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials
Olivia Pagani et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer
Ann H. Partridge et al.
NEW ENGLAND JOURNAL OF MEDICINE (2023)
ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)
S. Paluch-Shimon et al.
ANNALS OF ONCOLOGY (2022)
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
N. Harbeck et al.
ANNALS OF ONCOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Early Discontinuation of Endocrine Therapy and Recurrence of Breast Cancer among Premenopausal Women
Lindsay J. Collin et al.
CLINICAL CANCER RESEARCH (2021)
Estrogen levels in premenopausal patients (pts) with hormone-receptor positive (HR plus ) early breast cancer (BC) receiving adjuvant triptorelin (Trip) plus exemestane (E) or tamoxifen (T) in the SOFT trial: SOFT-EST substudy final analysis
M. Bellet et al.
CANCER RESEARCH (2019)
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
P. A. Francis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Hongchao Pan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer.
Richard G. Gray et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progress
Hyun-Ah Kim et al.
BMC CANCER (2016)
Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials
Meredith M. Regan et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The Modern Landscape of Endocrine Therapy for Premenopausal Women with Breast Cancer
Lorenzo Rossi et al.
BREAST CARE (2015)
Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
Prudence A. Francis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
Olivia Pagani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments
Peter C. Austin
STATISTICS IN MEDICINE (2014)
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
Christina Davies et al.
LANCET (2013)
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer
Emilio Bria et al.
LUNG CANCER (2009)
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
Michael Gnant et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)